knowledge -WSS

knowledge

author：comprehensive 2025-09-27 09:44:32 - browse：67345

Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to do a deal on a party bus?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Recording from the J.P. Morgan Healthcare Conference, we discuss how a spate of deals and some intermittent sunshine seem to have brightened the outlook for biotech at the outset of 2024. We also talk about the latest twist in the Sarepta Therapeutics saga, a ubiquitous dealmaker, and life on the party circuit.

For more on what we cover, here’s the news on Sarepta; here’s more on Nvidia; here’s the story on Centerview; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： John Green on his newest strategy for fighting tuberculosis

knowledge

leisure time

WSS

Readout Newsletter: Bristol, Sangamo, Gilead, and more

JPM: CVS says Medicare Advantage patients are impacting profits

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

How many hemophilia patients actually want gene therapy?

Morgan Health, with ambitious aims, wants you to know it’s still here

Readout Newsletter: Bristol, Sangamo, Gilead, and more

explore

knowledge

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Feng Zhang CRISPR delivery startup lays off quarter of staff

Medicare proposal to cover medical devices draws a mixed reaction

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Moonlake's readout produced a cash windfall. Risks remain

RaDonda Vaught links Vanderbilt hospital issues to patient death

Drug repurposing or repositioning? The language matters

Feng Zhang, Grail founder join forces on new gene editing startup

Medicare details structure of new drug price negotiation program

Federal weight loss drug coverage is 30 years out of date

focus

U.K. sequencing study surfaces new findings about tumor DNA

EPA limits use of carcinogenic gas for sterilizing medical devices

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Videos point to link between seizures and unexplained toddler deaths

explore

knowledge

leisure time

focus